Randomized Trial of Finerenone on Urinary Albumin-to-Creatinine Ratio in Type Diabetes and CKD

Figures

• 

  Figure 1. UACR response by background medication status. Of the 97 participants with UACR follow-up data, 96 (48 in each treatment group) had week 24 data. The remaining participant, for whom only week 12 data were available, was also included in the mixed-effects analysis. The P-value for interaction was obtained from the treatment × subgroup interaction term at week 24. GLP-1RA, glucagon-like peptide-1 receptor antagonist; RASi, renin-angiotensin system inhibitor; SGLT2i, sodium-glucose co-transporter 2 inhibitor; UACR, urinary albumin-to-creatinine ratio.

• 

  Figure 2. Changes in eGFR (a), serum potassium (b), and blood pressures (c for systolic and d for diastolic) by background medication status (none or single use, dual combination, and triple combination). The P-value for interaction was obtained from the treatment × subgroup interaction term at week 24. eGFR, estimated glomerular filtration rate.